Matuzumab: Solid tumor therapy humanized anti-EGFR monoclonal antibody

Drugs of the Future

Volumn 30, Issue 3, 2005, Pages 240-247

  Sorbera, L A ^a   Bozzo, J ^a   Bayes M ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GEMCITABINE; HUMANIZED EPIDERMAL GROWTH FACTOR RECEPTOR MONOCLONAL ANTIBODY; HUMAX; IMC 11F8; IMMUNOGLOBULIN G; MATUZUMAB; MEMBRANE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; NIMOTUZUMAB; PACLITAXEL; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RADIOTHERACIM; THERACIM H R3; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ACNEIFORM RASH; ALLERGIC REACTION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BRONCHOSPASM; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CELL SURVIVAL; CHOLANGITIS; CLINICAL TRIAL; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FEVER; FLUSHING; GUILLAIN BARRE SYNDROME; HEAD AND NECK CANCER; HEADACHE; HUMAN; HYPOKALEMIA; LIGAND BINDING; LIVER TOXICITY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MENSTRUATION DISORDER; MONOTHERAPY; MULTIPLE DRUG DOSE; NEUTROPENIA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHYSICAL DISABILITY; RASH; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKIN TOXICITY; SOLID TUMOR; STOMACH CANCER; TRANSCRIPTION REGULATION; UTERINE CERVIX CANCER; VOMITING;

EID: 18844361874     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2005.030.03.884922     Document Type: Article

References (41)

1. Ullrich, A., Schlessinger, J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990, 61: 203-12.
2. Alroy, I., Yarden, Y. The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 1997, 410: 83-6.
3. Todd, R., Wong, D.T. Epidermal growth factor receptor (EGFR) biology and human oral cancer. Histol Histopathol 1999, 14: 491-500.
4. Abe, Y., Odaka, M., Inagaki, F., Lax, I., Schlessinger, J., Kohda, D. Disulfide bond structure of human epidermal growth factor receptor. J Biol Chem 1998, 273: 11150-7.
5. Mendrola, J.M., Berger, M.B., King, M.C., Lemmon, M.A. The single transmembrane domains of ErbB receptors self associate in cell membranes. J Biol Chem 2002, 277: 4704-12.
6. Yarden, Y. The EGFR family and its ligands in human cancer: Signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001, 37(Suppl. 4): S3-8.
7. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103: 211-25.
8. Prenzel, N., Fischer, O.M., Streit, S., Hart, S., Ullrich, A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr-Relat Cancer 2001, 8: 11-31.
9. Davis, R.J. Signal transduction by the JNK group of MAP kinases. Cell 2000, 103: 239-5.
10. Ballif, B.A., Blenis, J. Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ 2001, 12: 397-408.
11. Kapeller, R., Cantley, L.C. Phosphatidylinositol 3-kinase. Bioessays 1994, 16: 565-76.
12. Gingras, A.-C., Kennedy, S.G., O'Leary, M.A., Sonenberg, N., Hay, N. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the AM(PKB) signaling pathway. Genes Dev 1998, 12: 502-13.
13. Datta, S.R., Brunet, A., Greenberg, M.E. Cellular survival: A play in three Akts. Genes Dev 1999, 13: 2905-27.
14. Romashkova, J.A., Makarov, S.S. NF-κB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999, 401: 86-90.
15. Mayo, L.D., Donner, D.B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 2001 98: 11598-603.
16. Raught, B., Gingras, A.-C., Sonenberg, N. The target of rapamycin (TOR) proteins. Proc Natl Acad Sci USA 2001, 98: 7037-44.
17. D'Errico, A., Barozzi, C., Fiorentino, M., Carella, R., Di Simone, M., Ferruzzi, L., Mattioli, S., Grigioni, W.F. Role and new perspectives of transforming growth factor-α (TGF-α) in adenocarcinoma of the gastro-oesophageal junction. Br J Cancer 2000, 82: 865-70.
18. Yacoub, L., Goldman, H., Odze, R.D. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: Correlation with prognosis. Mod Pathol 1997, 10: 105-12.
19. Bigner, S.H., Humphrey, P.A., Wong, A.J., Vogelstein, B., Mark, J., Friedman, H.S., Bigner, D.D. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 1990, 50: 8017-22.
20. Moscatello, O.K., Montgomery, R.B., Sundareshan, P., McDanel, H., Wong, M.Y., Wong, A.J. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene 1996, 13: 85-96.
21. Eischen, C.M., Schilling, J.D., Lynch, D.H., Krammer, P.H., Leibson, P.J. Fc receptor-induced expression of Fas ligand on activated NK cells facilitates cell-mediated cytotoxicity and subsequent autocrine NK cell apoptosis. J Immunol 1996, 156: 2693-9.
22. Sulica, A., Chambers, W.H., Manciulea, M., Metes, D., Corey, S., Rabinowich, H., Whiteside, T.L., Herberman, R.B. Divergent signal transduction pathways and effects on natural killer cell functions induced by interaction of Fc receptors with physiologic ligands or antireceptor antibodies. Nat Immun 1995, 14: 123-33.
23. Sung, M.W., Yasumura, S., Johnson, J.T., Van Dongen, G.A., Whiteside, T.L. Natural killer (NK) cells as effectors of antibody-dependent cytotoxicity with chimeric antibodies reactive with human squamous-cell carcinomas of the head and neck. Int J Cancer 1995, 61: 864-72.
24. Ciardiello, F., Tortora, G. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin Cancer Res 2001, 7: 2958-70.
25. Hambek, M., Solbach, C., Schnuerch, H.-G., Roller, M., Stegmueller, M., Sterner-Kock, A., Kiefer, J., Knecht, R. Tumor necrosis factor alpha sensitizes low epidermal growth factor receptor (EGFR)-expressing carcinomas for anti-EGFR therapy. Cancer Res 2001, 61: 1045-9.
26. Bruns, C.J., Kleespiess, A., Gossmann, A., Papyan, A., Bangard, C., Schneider, P.M., Kreysch, H.-G., Lackner, K., Hölscher, A.H. Contrast enhanced MRI as in vivo monitoring for the anti-angiogenic effect of EGF-R blockade in pancreatic cancer growing orthotopically in nude rats. Proc Am Assoc Cancer Res 2002, 43: Abst 2880.
27. Burger, A.M., Heiss, N.S., Kreysch, H.-G., Schandelmaier, K., Wirth, G., Fiebig, H., Grell, M. The humanized monoclonal anti-EGFR antibody EMD72000 potently inhibits the growth of EGFR-expressing human tumor xenografts insensitive to chemotherapeutic drugs. Proc Am Assoc Cancer Res 2003, 44(2nd ed): Abst 5719.
28. Amendt, C., Mantell, O., Peters, M., Yezhelyev, M., Jauch, K.-W., Geissler, E., Bruns, C.J. In vivo activity of humanized monoclonal anti-EGFR antibody EMD72000 in combination with gemcitabine on growth of primary pancreatic tumors and metastases in an orthotopic nude mouse model. Proc Am Assoc Cancer Res 2003, 44(2nd ed): Abst 6180.
29. Bier, H., Hoffmann, T., Haas, t., van Lierop, A. Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother 1998, 46: 167-73.
30. Lo, K.-M., Lan, Y., Zhang, X., Gillies, S.D. The role of ADCC effector function in the anti-tumor efficacy of anti-EGFR antibodies in a mouse xenograft model. AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 17-21, Boston) 2003, Abst A123.
31. Rosen, O., Hellmann, J., Golob, M., Kovar, A., Schubert, C., Reiffen, K.-A., Leuschner, J. Toxicity assessment of EMD 72000 in cynomolgus monkeys and comparison with human studies. Proc Am Assoc Cancer Res 2003, 44(2nd ed): Abst 4582.
32. Tillner, J., Golob, M., Vahoefer, U., Tabernero, J., Rosen, O., Kovar, A. Pharmacokinetics (PK) on the novel humanized anti-EGFR Mab EMD 72000. AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 17-21, Boston) 2003, Abst A110.
33. Bier, H., Hoffmann, T., Hauser, U., Wink, M., Öchler, M., Kovar, A., Müser, M., Knecht, R. Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx. Cancer Chemother Pharmacol 2001, 47: 519-24.
34. Hoffend, J., Mohammed, A., Eisenhut, M., Bosch, F., Dietz, A., Rosen, O., Kovar, A., Weber, D., Tillner, J., Haberkorn, U. Uptake of the anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 in tumors of subjects with head and neck squamous cell carcinoma (HNSCC). 40th Annu Meet Am Soc Clin Oncol (June 5-8, New Orleans) 2004, Abst 3043.
35. Vanhoefer, U., Tewes, M., Rojo, F. et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 2004, 22: 175-84.
36. Trarbach, T., Beyer, T., Schleucher, N., Stattaus, J., Mueller, S.P., Rojo, F., Tillner, J., Schmid, K.W., Seeber, S., Vanhoefer, U. Final results of a randomized phase I pharmacokinetic and pharmacodynamic study of weekly EMD 72000 (matuzumab), a humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody, in subjects with advanced gastrointestinal cancers. Ann Oncol 2004, 15(Suppl. 3): Abst 378O.
37. Tabernero, J., Rojo, F., Jimenez, E., Montaner, I., Santome, L., Guix, M., Rosen, O., Kovar, A., Salazar, R., Baselga, J. A phase I PK and serial tumor and skin pharmacodynamic (PD) study of weekly (q1w), every 2-week (q2w) or every 3-week (q3w) 1-hour (h) infusion EMD72000, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (pt) with advanced tumors. Proc Am Soc Clin Oncol 2003, 22: Abst 770.
38. Kollmannsberger, C., Schittenhelm, M., Honecker, F., Rosen, O., Tillner, J., Kanz, L., Bokemeyer, C. Epidermal growth factor receptor (EGFR) antibody EMD 72000 in combination with paclitaxel (P) in patients (pts) with EGFR-positive advanced non-small cell lung cancer (NSCLC): A phase-I study. Proc Am Soc Clin Oncol 2003, 22: Abst 2520.
39. Graeven, U., Vogel, I., Killing, B., Hinz, S., Von Bernstorff, W., Baselga, J., Rojo, F., Tillner, J., Gropp, P., Schmiegel, W. Phase I study of humanized IgG 1 anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 plus gemcitabine (Gem) in advanced pancreatic cancer. 40th Annu Meet Am Soc Clin Oncol (June 5-8, New Orleans) 2004, Abst 3061.
40. Van Cutsem, E., Tejpar, S., Verslype, C. Epidermal growth factor receptors inhibitors in colorectal cancer. Ann Oncol 2004, 15(Suppl. 3): Abst 6IN.
41. Therapeutic areas: Oncology. EMD Pharmaceuticals Web Site, February 18, 2005.